In This Article:
Biofrontera (ETR:B8FK) Full Year 2024 Results
Key Financial Results
-
Revenue: €21.7m (down 33% from FY 2023).
-
Net loss: €4.35m (loss widened by €3.98m from FY 2023).
-
€0.72 loss per share (further deteriorated from €0.12 loss in FY 2023).
B8FK Post-Clinical Trial Products
-
Approved (during full year): 1.
-
Launched (during full year): 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Biofrontera shares are up 6.1% from a week ago.
Risk Analysis
Be aware that Biofrontera is showing 3 warning signs in our investment analysis and 2 of those are a bit unpleasant...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.